Purpose: The aim of this study was to compare various acquisition and processing protocols for noninvasive glioma grading using either static or dynamic 18 F-FDopa PET. Methods: Dynamic studies were performed in 33 patients. Based on histopathological analysis, 18 patients had a high-grade (HG) tumor and 15 patients had a low-grade (LG) tumor. For static imaging, SUV mean and SUV max were calculated for different acquisition time ranges after injection. For dynamic imaging, the transport rate constant k 1 was calculated according to a compartmental kinetic analysis using an image-derived input function. Results: With the use of a 5-minute static imaging protocol starting at 38 minutes after injection, newly diagnosed HG tumors could be distinguished from LG tumors with a sensitivity of 70% and a specificity of 90% with a threshold of SUV mean of 2.5. In recurrent tumors, a sensitivity of 100% and a specificity of 80% for identifying HG tumors were obtained with a threshold set to 1.8. Dynamic imaging only slightly, but nonsignificantly, improved differential diagnosis. Conclusions: Static and dynamic imaging without blood sampling can discriminate between LG and HG for both newly diagnosed and recurrent gliomas. In dynamic imaging, excellent discrimination was obtained by considering the transport rate constant k 1 of tumors. In static imaging, the best discrimination based on SUV was obtained for SUV mean calculated from a 5-minute acquisition started at 38 minutes after injection.
B rain imaging is a promising approach for noninvasive tumor grading. 1 The potential of PET/CT imaging for grading brain tumors PET/CT with labeled amino acids or analogs, such as methionine, tyrosine, leucine, alanine, and isobutyric acid, has been reported, involving either dynamic 2 or static studies. 3, 4 The clinical application of dynamic analysis of L-3,4-dihydroxy-6-18 F-fluoro-phenyl-alanine ( 18 F-FDopa) in brain tumors has also been described. 2, 5, 6 Chen et al 7 found no significant difference between high-grade (HG) and lowgrade (LG) brain tumors using the SUV max in the tumor for static 18 F-FDopa (P = 0.40) with 7 newly diagnosed and 23 recurrent tumors, where the static images were obtained using 20-minute acquisition starting 10 minutes after injection. Schiepers et al 8 reported significant differences (P G 0.01) between HG and LG brain tumors using dynamic 18 F-FDopa and static 18 F-FDopa with 16 newly diagnosed and 35 recurrent tumors, without determining whether dynamic imaging should be preferred. Using static PET imaging (20-minutes acquisition starting at 10 minutes after injection) and SUV, Fueger et al 9 also found a significant difference (P = 0.001) between HG and LG brain tumors for 22 newly diagnosed tumors but not for 37 recurrent tumors (P = 0.41). They suggested that 18 F-FDopa could be useful for distinguishing tumor recurrence from radiation necrosis. So far, there are not much published data regarding the comparison between the diagnostic performance of static and dynamic 18 F-FDopa PET imaging. 6 In this work, we investigated several acquisition and processing protocols of noninvasive 18 F-FDopa PET/CT (without blood sampling) for glioma grading. We compared the accuracy of tumor grading based on tumor SUV mean and SUV max calculated using static PET/CT corresponding to various time ranges after acquisition and based on the influx rate constants measured using a dynamic acquisition and an image-derived arterial input function. Static and dynamic methods have never been compared in this context. A goal was to determine if a static acquisition could distinguish HG and LG brain gliomas or if dynamic imaging with compartmental analysis was needed.
PATIENTS AND METHODS

Patients
Thirty-three patients (5 women, 28 men) were scanned using PET/CT (Table 1) without carbidopa premedication and fasting. The mean (SD) patient age was 51 (16) years (range, 22Y97 years). Ten patients presented with recurrent tumors and previously received antiepileptic treatment (levetiracetam or sodium valproate). All 10 went through surgical resection. In addition to surgery, 7 patients received chemotherapy (temozolomide [alkylating agent] or bevacizumab, and irinotecan [antiangiogenaic therapy]) or radiation, whereas 1 patient underwent radiation therapy only. Three patients presented with recurrent tumors and had not received treatment. Twenty patients presented with newly diagnosed tumors and had received antiepileptic treatment without chemotherapy and radiation. The protocol was approved by our ethics committee, and informed consent was given by patients or their relatives.
PET/CT IMAGING
The recommended injected activity was 2.2 MBq/kg per patient. Patients were injected with activities between 120 and 200 MBq of 18 F-FDopa (IASOdopa, IASON GmbH, Graz, Austria). Images were acquired with a PET/CT GEMINI TF (Philips Healthcare, Cleveland, OH).
First, a thoracic CT acquisition was performed (120 kV, 100 mA, pitch:1:1, 60-cm transverse FOV, 512 Â 512 pixels, 2 Â 2-mm 2 pixel size, and 2-mm thickness). Then, a dynamic thorax PET acquisition of 1-minute 50-second duration was started at the time of tracer injection (between 5 and 7 mL per 30 seconds). One bed position (18-cm longitudinal FOV) including the thorax and centered on the heart was acquired in list mode. This 1-minute 50-second dynamic acquisition was reconstructed in 10 frames of 11 seconds using the 3D OSEM algorithm including attenuation and scatter corrections. The reconstructed voxel size was 4 Â 4 Â 4-mm 3 (smallest voxel size achievable in our scanner for a thorax acquisition). The motivation for this initial thoracic acquisition was to obtain an accurate image-derived arterial input function (IDAIF) of 18 F-FDopa. For each thorax PET/CT, a 10-mm thick volume of interest (VOI) in the descending aorta was drawn manually on the CT images and used to estimate the IDAIF. 10 The PET activity measurements in the aorta VOI were corrected from partial volume effect using a recovery coefficient method. 11 The recovery coefficient was calculated by convolving the binary aorta VOI with a 3D Gaussian function (6.5-mm full width at half maximum), modeling the point spread function in the reconstructed images. The 6.5-mm value was measured using a glass capillary filled with 18 F, after acquiring and reconstructing the data using exactly the same protocol as in patients. Only spill-out activity was compensated for. Activity from outside the aorta detected within the aorta VOI could be neglected, thanks to very early acquisition, before significant tissue distribution of the tracer and the lack of any radioactivity accumulation close to the aorta at this time.
For each patient, we visually checked the aorta 18 F-FDopa time-activity curve (TAC) (blue line in Fig. 1A and B ). As the IDAIF was not sampled after 1 minute 50 seconds, we completed the curve up to 40 minutes as needed by the subsequent compartmental analysis, by fitting the decreasing part of the aorta curve with a decreasing monoexponential function: y = a exp(jt / b) + c (red line in Fig. 1A and B ). The c offset value accounted for the residual 18 F-FDopa in the blood. Its value was estimated as the averaged c value obtained using exactly the same model on a set of 20 AIF measured in 18 F-FDopa scans acquired as part of a different research protocol, including a late image on the aorta. The green points in Figure 1A correspond to the c values obtained in these 20 patients, at the times at which the late scan was acquired. The values resulting from the fit were used to complete the decreasing part of the aorta up to 40 minutes, with a time sampling of 30 seconds.
A dynamic brain PET acquisition of 40 minutes duration was performed after the thoracic acquisition. One bed position (transaxial FOV, 25.6 cm) centered on the brain was acquired in list mode, starting 3 minutes after the injection of 18 F-FDopa. The reconstructed voxel size was 2 Â 2 Â 2-mm 3 . For the static image analysis, a PET image corresponding to the 40-minute acquisition was reconstructed. In addition, 2 time frames were reconstructed based on the method in Schiepers et al 8 : one corresponding to 15 to 25 minutes and a late interval corresponding to the last 5 minutes of our dynamic acquisition (38Y43 minutes after injection). The 40-minute dynamic acquisition was also reconstructed in 40 frames of 1 minute for kinetic modeling. Owing to the dynamic imaging protocol, no imaging was performed after 43 minutes, to avoid keeping the patients longer on the scanning table. The approximately 1-minute time lag between the thoracic and brain acquisitions was necessary for shifting the bed, repositioning the patient's arms along the body, and triggering the camera for the brain acquisition.
The brain CT acquisition was performed after the PET acquisition (120 kV, 150 mA, pitch:1:1, 60-cm transverse FOV, 512 Â 512 pixels, 2 Â 2-mm 2 pixel size, and 2-mm thickness) without iodine IV contrast agent. Reconstructed images were 2-mm thick and had 2 Â 2-mm 2 pixel size. For thorax and brain, the CT volume was used for attenuation correction and as an anatomic reference for PET/CT image fusion.
Image Analysis
Images were first inspected visually, then static and dynamic data were analyzed. For each subject, a 2-dimensional circular tumor region of interest (ROI) with a volume of 35-mm 3 was automatically drawn and centered on the voxel with the SUV max in the PET static image of 40-minute duration. This same ROI was applied to both static and dynamic analyses. Another VOI was manually drawn on the PET static image of 40-minute duration to determine the tumor volume, by encompassing all the tumor areas. All HG and LG tumors were relatively easy to delineate, thanks to the high contrast between tumor and background. The number of voxels in this VOI was converted into a tumor volume.
Static Image Analysis
The tumor SUV mean and SUV max were calculated within the tumor ROI for the 3 acquisition times. The first time range (between 15 and 25 minutes after injection, called median) yielded SUV mean,median and SUV max,median . The second interval (between 38 and 43 minutes after injection, called late) yielded SUV mean,late and SUV max,late . The third interval (between 3 and 43 minutes after injection, called total) yielded SUV mean,total and SUV max,late .
Nonparametric receiver operating characteristic (ROC) curve analysis was used for all time ranges to characterize the performance of all SUV indices in distinguishing between HG and LG tumor (ROCR 12 ).
Dynamic Image Analysis
We used a 2-compartment model adapted from the one used by Schiepers et al, 8 without metabolite correction. The first compartment was the arterial blood mean activity [C p ]. From arterial blood, the radiotracer passes into the so-called free compartment ( f ) corresponding to nonspecific (n) uptake and specific uptake (b) or metabolism mean activity [C fnb ]. The transport and uptake rates of the tracer k 1 (in mL/g/min) for transport of [C p ] to [C fnb ], k 2 (per minute) for transport of [C fnb ] to [C p ] are assumed to be linearly related to the concentration differences between the 2 compartments C p and C fnb . If C p (t) and C fnb (t) are the radioactivity concentrations at time t, in minutes, for each compartment, the measured PET data corresponds to C PET (t) = C p (t) + C fnb (t).
The model parameters can be estimated by fitting the model to the measured PET data, using the arterial radioactivity concentration C p (t) as the input function. For our clinical study, including only outpatients, the arterial input function was estimated as described in PET/CT Imaging section.
Our kinetic model was solved using Lawson-Hanson nonnegative least square algorithm, 13 Receiver operating characteristic curve analysis was used to assess the performance of the transfer rate k 1 in discriminating between LG and HG tumors (ROCR 12 ).
Statistical Analysis
The significance of the difference between the areas under the ROC curves was tested using a nonparametric test, with P G 0.05 considered as significant. 14 
RESULTS
Histopathology
The distribution of tumor types, grades, and volumes is listed in Table 1 . Of the patients, 18 (54%) had an HG tumor and 15 (46%) had an LG tumor. Seven tumors (21%) were classified as glioblastoma, 19 (57.6%) as oligodendroglioma. Of 28 lesions, 8 (24%) were classified as grade IV, 10 (30%) as grade III, and 15 (46%) as grade II, and there was no grade I lesion. Twenty lesions were newly diagnosed, and 13 were recurrent brain tumors.
Only 1 LG tumor had a volume less than 2.9 cm 3 , whereas all HG tumors were larger than 3.9 cm 3 . Given the spatial resolution in our reconstructed images (6.5 mm), partial volume effect should thus not introduce a large bias in our measurements.
Static Imaging
When considering all tumors, whatever the time interval and for SUV mean and SUV max , there was a significant difference (P G 0.02) between the SUV measured in the HG and LG tumors ( Table 2 ). Figure 2 shows 2 PET static (40 minutes) slices and an example of typical TACs for HG ( Fig. 2A) and LG (Fig. 2B) tumors. The cerebellum curves illustrate TACs measured in healthy tissue.
As expected from the TAC seen in Figure 2 , for all tumors (HG and LG), on average, SUV mean,median had a higher value than SUV mean,late ( Table 2) .
When considering newly diagnosed and recurrent tumors together, the ROC curves describing the discrimination between HG and LG tumors are shown in Figure 3A for SUV mean,late (mean [SD] area under the curve [AUC], 0.88 [0.06]). The AUCs is given in Table 4 , as well as the threshold (1.8) corresponding to the operating point (OP) maximizing the sum of sensitivity and specificity, and associated sensitivity and specificity (66% specificity and a 94% sensitivity). Similarly, the AUC, OP threshold, and corresponding sensitivity and specificity are given for all indices and all tumor groups in Table 4 .
In the newly diagnosed tumors only, there was also a significant difference between HG and LG tumors whatever the SUV index (P G 0.05) ( Table 2 ). Figure 3B shows the corresponding ROC curves, and Table 4 presents their characteristics.
In the recurrent tumors only, only the SUV mean indices were significantly different between HG and LG tumors (P G 0.01), whereas the SUV max indices were not (P 9 0.06) ( Table 2 ). Figure 3C shows the corresponding ROC curves, and Table 4 presents their characteristics.
The comparison of the AUC corresponding to the different SUV for a given group of tumors (all, newly diagnosed only, or recurrent only) did not show any statistically significant difference.
Dynamic Imaging
An example of aorta VOI in the axial (Fig. 1C, top) and sagittal (Fig. 1C, bottom) images is shown in Figure 1 . The TAC in the VOI corresponds to the first 1.5 minutes of acquisition after injection ( Fig. 1A and B , blue). It shows 18 F-FDopa passing through the aorta, yielding an estimate of the arterial input function. The result of the monoexponential fit of the decreasing part of the curve is also shown ( Fig. 1A and B, red) .
The highest tracer uptake in the HG tumors occurred at 8.5 (1.6) minutes and at 8.0 (2.9) minutes for LG tumors (no-significant [NS]). Table 3 summarizes the k 1 and k 2 values for all tumors and for the subgroups of newly diagnosed and recurrent tumors. When considering all tumors, mean k 1 was significantly different between LG and HG (P G 0.02), unlike mean k 2 . The same was true for newly diagnosed and recurrent tumors ( Table 3) .
The ROC curves for k 1 are shown in Figure 3A to C for the different tumor groups, and the corresponding curve features are summarized in Table 4 .
There was no statistically significant difference between the AUC obtained with k 1 for the newly diagnosed tumors and the recurrent tumors, suggesting that FDopa PET kinetic analysis could distinguish between HG and LG tumors not only for newly diagnosed tumors but also for recurrent tumors.
DISCUSSION
We analyzed differences in 18 F-FDopa SUVs, k 1 and k 2 between HG and LG lesions in both newly diagnosed and recurrent gliomas. We also described a new noninvasive approach to estimate k 1 from dynamic imaging without any blood sampling.
Static Imaging for Grading Gliomas
Based on our dynamic acquisition protocol, we considered 3 static acquisition times after injection. Our group composed of all tumors demonstrate that HG tumors could be distinguished from LG tumors using all SUV mean indices, whatever the postinjection acquisition time (SUV mean,median , SUV mean,late , and SUV mean,total ) with P = 0.001 ( Table 2) . Although the highest AUC at 0.88 (0.06) was observed for SUV mean,late , our sample could not yield evidence of any statistically significant difference between AUC associated with SUV mean,median , SUV mean,late , and SUV mean,total : all acquisition times yielded close results in terms of differential diagnosis.
In their study (11 newly diagnosed lesions, 28 recurrent tumors, and 27 clinically stable patients), Chen et al 7 found no significant difference between 18 LG and 48 HG tumors based on 18 F-FDopa uptake (P = 0.40) when using a static image of 10 to 30 minutes after injection and measuring the ratio of tumor to contralateral normal tissue uptake. No result regarding the discrimination of the HG and LG lesions based on SUV was included.
Focusing on newly diagnosed tumors only, our results demonstrate that HG tumors could be distinguished from LG tumors based on SUV mean and on SUV max with the median, late, and total time range (P G 0.05). The HG and LG recurrent tumors could be distinguished using static imaging only with SUV mean . This might be due to the variability of SUV max , which is more affected by noise than SUV mean because SUV max is calculated from a single voxel and/or to the lack of statistical power due to the relatively small number of patients in our subgroups. Our results therefore suggest that SUV mean should be preferred for differential diagnosis between HG and LG tumors using static imaging and that when using SUV mean , HG and LG gliomas could be identified for all acquisition times we considered and whatever the type of tumors (newly diagnosed or recurrent tumors).
The early acquisition time in the study by Schiepers et al 8 (15Y25 minutes for 33 newly diagnosed lesions) corresponds to our median acquisition time. They found a trend toward higher uptake values for HG tumors, with a large overlap between tumor grades. This is consistent with our results as we found a significant difference between HG and LG newly diagnosed tumors for SUV mean,median (P = 0.015). In our clinical context, we could not confirm that optimal discrimination between HG and LG tumors in a static image was obtained 60 to 70 minutes after injection as reported by Schiepers et al. 8 The difference in grading accuracy observed at 38 minutes after injection and at 60 minutes after injection might still be worth investigating.
Our results are also consistent with the results of Fueger et al, 9 who found SUV max of HG tumor to be 4.2 (1.3) versus SUV max of LG tumor to be 2.3 (1.3) (P = 0.005) for newly diagnosed tumors (20-minute acquisition starting at 10 minutes after injection), whereas we observed SUV max of HG tumor to be 4.0 (1.3) versus SUV max of LG tumor to be 2.5 (1.0) (P = 0.008, 40-minute acquisition starting at 3 minutes after injection).
If only static imaging is available, our recommendation is thus to measure SUV mean , preferably at late times. It yields high AUC whatever the tumor type (newly diagnosed or recurrent tumors) ( Table 4 ). The LG and HG tumors could be distinguished using SUV mean,late of a 5-minute static 18 F-FDopa PET acquisition starting at 38 minutes after injection, which is easily feasible in clinical routine.
Dynamic Imaging for Grading Tumors
For kinetic analysis, we estimated the AIF in the aorta instead of the middle cerebral artery to minimize partial volume effect. Other brain studies have used AIF measured in the aorta for measurements of cerebral glucose metabolism with FDG. 10 When considering AIF in the transverse sinus, Schiepers et al obtained k 1 = 0.347 (0.399) (newly diagnosed tumors), that is, a coefficient of variation of 1.15. In our results, we had k 1 = 0.244 (0.098) (coefficient of variation of 0.40) suggesting a smaller variability of our approach, possibly due to less uncertainty introduced by partial volume correction. The mean differences between the absolute k 1 and k 2 values reported in Schiepers et al 8 and ours (in newly diagnosed tumors) were C k 1 = 0.103 and C k 2 = 0.106 for HG. These differences are partly explained by the different approaches to estimate the AIF. An important conclusion is that the discriminating power of k 1 was demonstrated in both studies, suggesting that the discrimination is robust with respect to potential bias in AIF estimates.
We repeated all analyses using a 3-compartment model. 6 The results (not shown) were very close to those described in this article with the 2-compartment model, and the transport rate k 3 was always close to zero. The differences obtained when considering the 2-or 3compartment model were C k 1 = 0.0042 (0.0060) (NS) and C k 2 = 0.0014 (0.0015) (NS). All conclusions of this study were exactly the same for the 2 models.
The k 1 parameter could clearly distinguish between LG and HG tumors for newly diagnosed lesions (P = 0.005), recurrent lesions (P G 0.02), and all lesions (P = 0.001) unlike k 2 parameter. When considering all tumors, the AUC for k 1 (0.92 [0.05]) was higher than that for SUV mean,late (0.88 [0.06]) although the difference was not significant.
For all tumor groups, the AUC measured when discriminating between HG and LG tumors was always higher with k 1 compared with any SUV. Yet, the difference was never significant, suggesting that the increased complexity associated with dynamic imaging compared with static imaging does not bring significantly increased accuracy in differential diagnosis.
Unlike Chen et al 7 who found no difference in TAC shapes between HG and LG tumors, our HG tumor curves were always characterized by a faster rise of uptake than the LG tumor curves (Fig. 2) .
The highest tracer uptake in the tumor generally occurred between 5 minutes and 12 minutes after injection in our study, with mean (SD) time of 8.5 (1.6) minutes for HG tumors and 8.0 (2.9) minutes for LG tumors. This is slightly earlier than reported by Schiepers et al 8 (12.7 minutes for HG tumors, 15.7 minutes for LG tumors) and by Chen et al 7 (between 10 and 30 minutes). The differences in peak times in these studies might be explained by different injection protocols (no description of the injection protocols in Schiepers et al 8 In their publication, Schiepers et al 8 used the 2-compartment model, with similar imaging and processing procedures as ours. They found k 1 = 0.285 per minute and k 2 = 0.195 per minute for 18 HG tumors and k 1 = 0.170 per minute and k 2 = 0.145 per minute for 11 LG tumors. They reported a statistically significant difference between LG and HG tumors for k 1 (P G 0.01), similar to our findings where k 1 discriminated between LG and HG tumors with P G 0.002 for all tumor groups. Compared with Schiepers et al, we demonstrated that HG-LG differential diagnosis could also be obtained using static imaging only, without the need for an AIF estimate.
Finally, the higher transport k 1 found in HG tumors compared with LG tumors was observed regardless of whether the tumor was newly diagnosed or recurrent.
CONCLUSIONS
Our work confirmed the usefulness of 18 F-FDopa for differential diagnosis between LG and HG glioma in newly diagnosed tumors. We demonstrated for the first time that LG and HG tumors could be distinguished in recurrent gliomas using static 18 F-FDopa PET.
LG and HG tumors could be distinguished using SUV mean,late of a 5-minute static 18 F-FDopa PET acquisition performed 38 minutes after injection. The discrimination was slightly but not significantly improved when dynamic images were acquired and analyzed using a 2-compartment model and an image-derived arterial input function. These results suggest that accurate glioma grading is achievable using static 18 F-FDopa PET/CT without the need to perform any blood sampling.
